Evidence for efficacy is based on the results from the NALA trial.
MyPathway points to chemotherapy-free treatment.
Arsenic trioxide Mylan is a generic of Trisenox, which has been authorised in the EU since 2002.
Rapid treatment uptake and similar outcomes in patients with metastatic melanoma.
Looking into future design of clinical trials in a tissue-agnostic fashion